In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durect Corp.

www.durect.com

Latest From Durect Corp.

Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

US FDA Reprimands Arog Pharmaceuticals For Promo Of Investigational AML Drug

Third enforcement letter of the year cites meeting exhibit and webpage that suggest crenolanib is safe and effective for an unapproved use.

Advertising, Marketing & Sales Enforcement

PTI’s Remoxy: Negative FDA Panel Review May Be The End Of Abuse-Deterrent Opioid's Road

Concerns that the extended-release oxycodone product poses the same potential for intravenous abuse as Endo’s withdrawn Opana ER drive FDA advisory committee recommendation against approval, laying the groundwork for a fourth complete response letter; FDA’s comparison of Remoxy to Opana during the meeting ‘borders on slanderous,’ PTI CEO Barbier tells Scrip, predicting sponsors will be dissuaded by the shifting regulatory goalposts for abuse-deterrent formulations.


Advisory Committees Drug Review

Pipeline Watch: Phase III Starts With VX-445, Reproxalap And AVXS-101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Site Specific
      • Transdermal
  • Therapeutic Areas
  • Hepatic (Liver)
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Durect Corp.
  • Senior Management
  • James E Brown, DVM, Pres. & CEO
    Matthew J Hogan, CFO
    Michael H Arenberg, SVP, Corp. & Bus. Dev.
    Felix Theeuwes, DSc, Chmn. & CSO
    WeiQi Lin, MD, PhD, SVP, R&D, R&D Bus. Dev.
    Robert M Janosky, VP, Strategic Planning & Bus. Dev.
    Myriam Theeuwes, DDS, SVP, Clin. Dev.
  • Contact Info
  • Durect Corp.
    Phone: (408) 777-1417
    10260 Bubb Rd.
    Cupertino, CA 95014-4166
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register